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MaOBJECTIVES The aim of this review is to describe the incidence, features, predisposing factors, and outcomes
of prosthetic valve endocarditis (PVE) after transcatheter valve replacement (TVR).
BACKGROUND Very few data exist on PVE after TVR.
METHODS Studies published between 2000 and 2013 regarding PVE in patients with transcatheter aortic valve
replacement (TAVR) or transcatheter pulmonary valve replacement (TPVR) were identiﬁed through a systematic
electronic search.
RESULTS A total of 28 publications describing 60 patients (32 TAVRs, 28 TPVRs) were identiﬁed. Most TAVR patients
(66% male, 80  7 years of age) had a very high-risk proﬁle (mean logistic EuroSCORE: 30.4  14.0%). In TPVR patients
(90% male, 19  6 years of age), PVE was more frequent in the stenotic conduit/valve (61%). The median time between
TVR and infective endocarditis was 5 months (interquartile range: 2 to 9 months). Typical microorganisms were mostly
found with a higher incidence of enterococci after TAVR (34.4%), and Staphylococcus aureus after TPVR (29.4%). As
many as 60% of the TAVR-PVE patients were managed medically despite related complications such as local extension,
embolism, and heart failure in more than 50% of patients. The valve explantation rate was 57% and 23% in balloon- and
self-expandable valves, respectively. In-hospital mortality for TAVR-PVE was 34.4%. Most TPVR-PVE patients (75%)
were managed surgically, and in-hospital mortality was 7.1%.
CONCLUSIONS Most cases of PVE post-TVR involved male patients, with a very high-risk proﬁle (TAVR) or underlying
stenotic conduit/valve (TPVR). Typical, but different, microorganisms of PVE were involved in one-half of the TAVR and
TPVR cases. Most TPVR-PVE patients were managed surgically as opposed to TAVR patients, and the mortality rate was
high, especially in the TAVR cohort. (J Am Coll Cardiol Intv 2015;8:334–46) © 2015 by the American College of Cardi-
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AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
IE = infective endocarditis
PVE = prosthetic valve
endocarditis
TAVR = transcatheter aortic
valve replacement
TVR = transcatheter valve
replacement
TPVR = transcatheter
onary valve replacement
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335and change their clinical impact and prognosis. This
is the case with prosthetic valve endocarditis (PVE),
a rare (3 to 9 cases per 100,000 people) but complex
and life-threatening disease.
Although a few TVR series have reported the inci-
dence of early infective endocarditis IE) (Online
Refs. 1–9) (Figures 1 and 2), data on PVE in the ﬁeld
of transcatheter valves are limited to case reports or
small series (1–28, Online Ref. 10), which precluded
any appropriate evaluation of the clinical character-
istics of patients with this syndrome as well as of its
management and prognosis. The objective of this
systematic review was therefore to provide further
insight into the baseline characteristics, incidence,
disease features, management, and clinical outcomes
of patients with IE as a complication of TVR (trans-
catheter aortic valve replacement [TAVR] and trans-
catheter pulmonary valve replacement [TPVR]).
METHODS
All relevant articles in English about TAVR/TPVR and
PVE published between December 2000 and June
2013 were systematically searched in BioMedCentral,
Google Scholar, and PubMed. The following query
terms were used: transcatheter/percutaneous pul-
monary/pulmonic valve replacement/implantation,
transcatheter/percutaneous aortic valve replacement/
implantation, transcatheter heart valve, infective
endocarditis, prosthetic valve endocarditis, valve
infection, congenital heart disease treatment and
modiﬁed Duke’s criteria. Further studies were sought
by means of a manual search of secondary sources,
including references from primary articles (backward
snowballing) and contacts with international experts.
We also searched for these topics as case reports in
major cardiology meetings between 2004 and 2012.
Citations were ﬁrst screened at the title/abstract
level by 2 independent reviewers (I.J.A.S., H.B.R.).
Potential divergences were resolved after consensus
to gather all pertinent case reports and case series
concerning PVE in TAVR and TPVR. Only cases with
deﬁnite endocarditis according to modiﬁed Duke
criteria were included (Online Refs. 11,12). Some
additional cases of “probable endocarditis” were also
included due to high suspicion of actual PVE and
limited sensitivity of the diagnostic criteria in their
particular context. Early PVE was deﬁned, according
to the guidelines, as that occurring within the ﬁrst 12
months after the valve replacement (Online Ref. 11).
Gathered data included baseline clinical, echocar-
diographic, and TVR procedural characteristics. Data
on PVE clinical presentation, invasive procedures
(any potential source of infection), etiology, in-hospital or 30-day complications, and mor-
tality at any time point were also gathered.
Main baseline characteristics of the TAVR-
PVE patients were compared with those of
patients included in previous TAVR registries
(Online Refs. 13–20), the PARTNER (Place-
ment of AoRTic TraNscathetER Valve) trial
(Online Refs. 6,7), and largest surgical series
including the main types of aortic bio-
prosthesis (Online Refs. 21–25). A similar
comparison was also performed for TPVR-
PVE patients, including the largest TPVR
series (Online Refs. 26–30) and the largest surgical
series that reported the incidence of PVE in congen-
ital heart disease (Online Ref. 31), pulmonary valve
replacement (Online Ref. 32), and Ross intervention
(Online Ref. 33).
Categorical variables were reported as n (%), and
continuous variables as mean  SD or median (25th
to 75th interquartile range) depending on variable
distribution.
pulmRESULTS
A total of 60 patients who underwent TVR, including
32 TAVR (1–16) and 28 TPVR (17–28), and who had PVE
were included in the study. All cases were published
between 2006 and 2013 (Online Table 1 for biblio-
graphic sources and type of articles). The main base-
line characteristics of TAVR and TPVR populations
are summarized in Tables 1 and 2, respectively. The
mean age of TAVR patients was 80  7 years, 66% of
them were men, and the mean logistic EuroSCORE
was 30.4  14.0%. A comparison of these data with
the data on the patients included large TAVR regis-
tries, the PARTNER trial (Online Refs. 6–9,19–22), and
in surgical studies (Online Refs. 22–25) is shown in
Figure 3.
TPVR patients were a much younger population
(mean age, 19  6 years), and only 10% of them were
women. Tetralogy of Fallot was the most common
underlying disease, and most patients (53%) had a
homograft as a right ventricular–pulmonary artery
conduit. The mean time between surgery and the
TPVR procedure was 10  3 years. Stenosis of the
valve conduit was the most common reason for TPVR
(60%). Baseline characteristics of the patients with
PVE compared with those included in large TPVR
series are shown in Figure 4.
PROCEDURAL AND IN-HOSPITAL COURSE OF TVR
PROCEDURES. The main characteristics of TAVR
and TPVR procedures are shown in Tables 1 and 2,
respectively. Of the TAVR patients, 58% had received
FIGURE 1 Incidence of Early Infective Endocarditis After TAVR and Surgical Aortic
Valve Replacement
Incidence of early (1 year) infective endocarditis after TAVR (A) and surgical aortic valve
replacement (B). *Online References. TAVR ¼ transcatheter aortic valve replacement.
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336a balloon-expandable Edwards SAPIEN/SAPIEN XT
valve (Edwards Lifesciences, Irvine, California) and
42% received a self-expandable CoreValve system
(Medtronic, Minneapolis, Minnesota). The trans-
catheter valve was replaced via a transfemoral and
transapical approach in 66% and 34% of patients,
respectively. Post-procedural echocardiographic data
were available for 21 patients, and the presence of
mild or greater residual aortic regurgitation (AR) was
observed in 16 of them (76%), with as many as 5
patients (24%) with moderate AR. This incidence of
residual AR was higher than that observed in previous
TAVR registries (mild or greater, 45.3%; moderate to
severe, 11.8%) and in both cohorts of the PARTNER
trial (mild or greater, 54%; moderate to severe, 12.3%)
(Online Refs. 6–9,19–22). All patients who had TPVR
had received a balloon-expandable Melody valve
(Medtronic) implanted via the transfemoral venous
approach; no data on hemodynamic results of the
procedure were provided in any of the TPVR studies.The location and environmental conditions where
the interventions took place were reported in 2 TAVR
studies only: a 4-case series that described a hybrid
room as the usual place for TAVR procedures (Online
Ref. 34) and the catheterization laboratory in a case
report (Online Ref. 23). In the TPVR population,
no information concerning the place where the
interventions were performed was provided.
Data on antibiotic prophylaxis were not detailed
in most cases. A wide variety of intravenous antibi-
otic regimens were administered including ampi-
cillin, vancomycin  ciproﬂoxacin, cefazolin 
gentamicin, or teicoplanin. No details were provided
on whether single or multiple antibiotic doses were
administered.
All procedures were considered successful in the
TAVR and TPVR groups. In-hospital complications
were reported exclusively in TAVR cases and included
complete atrioventricular block leading to permanent
pacemaker implantation in 2 cases, pneumonia/
tuberculosis reactivation in 2 cases, and acute kidney
injury requiring dialysis in 2 cases. The median length
of stay after the TAVR procedure for those patients
who did not present in-hospital PVE (all but 2 cases)
was 6 days (interquartile range: 2 to 7 days).
CLINICAL FEATURES OF PVE POST-TVR. The main
individual characteristics regarding the timing, clin-
ical presentation, etiology, and location of PVE in the
TAVR and TPVR groups are shown in Tables 3 and 4,
respectively. The median time from the intervention
to the diagnosis of PVE was 5.0 months (interquartile
range: 3 to 9 months). The timeline of initial PVE
symptoms is shown depicted in Figure 5.
The suspected sources of PVE were as follows:
respiratory infections (TAVR, 4 cases; TPVR, 2
cases), dental interventions (TAVR, 3 cases; TPVR,
2 cases), skin infections (TAVR, 3 cases; TPVR, 2
cases), and urological (TAVR, 2 cases; TPVR, 0 cases)
or gastrointestinal interventions (TAVR, 1 case).
The 3 main sources (dental and respiratory/skin
infections) were the same for both types of TVR, but
a health care–related origin was more common in
TAVR patients (42.1%) than in TPVR patients (18.2%)
(p ¼ 0.246). The source of infection remained un-
determined in as many as 50% of the patients. Very
little information was provided on the management
of PVE prophylaxis after the TVR procedure, and
failure to comply with recommendations was re-
ported in 2 cases (18,22). A history of PVE existed in
2 pulmonary cases.
In 2 cases, only criteria for “possible” PVE were
achieved, but given the high suspicion, they were
ﬁnally included in the present review (7,8).
FIGURE 2 Incidence of Early Infective Endocarditis After TPVR and Surgical
Pulmonary Valve Replacement
Incidence of early (1 year) infective endocarditis after TPVR (A) and surgical pulmonary
valve replacement (B). *Online References. TPVR ¼ transcatheter pulmonary valve
implantation.
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337Fever (80%) and heart failure (22%) were the most
common initial symptoms of PVE in the TVR popu-
lation. Speciﬁc symptoms derived from septic emboli
such as neurological symptoms (exclusively in the
TAVR group) or pulmonary abscess in the TPVR group
also occurred in 12.5% and 3.7% of the patients,
respectively. Less frequent symptoms included
cutaneous stigmata, local chills, loss of appetite,
macrophage activation syndrome, and limb ischemia
due to septic emboli. One patient remained asymp-
tomatic, and PVE was suspected by new valve
regurgitation and later conﬁrmed by microbiological
ﬁndings (Online Ref. 35).
The location of PVE as determined by trans-
esophageal echocardiography is schematically depic-
ted in Figure 6. The presence of vegetation was
detected in 58.3% of the patients (50.0% and 68.4% in
the TAVR and TPVR groups, respectively). In the
TAVR group, the vegetation was located on the
transcatheter valve leaﬂets in 7 patients (21.9%), on
the valve stent frame in 2 patients (6.2%), and
affected both structures in 3 patients (9.2%). Also,
tricuspid and mitral valves presented vegetation in 1
(3.1%) and 3 patients (9.4%), respectively. The infec-
tion was restricted to the prosthetic valve in all TPVR
cases (Table 5). No valve involvement could be
conﬁrmed in 4 patients (3 patients in the TAVR group
and 1 in the TPVR group), with initial criteria for
deﬁnite PVE and good response to antibiotic therapy.
The main microbiological ﬁndings differed in the
TAVR and TPVR groups (Table 5). Although Entero-
coccus was the most frequent microorganism re-
sponsible for PVE in TAVR patients (34.4%),
Staphylococcus aureus was predominant among TPVR
patients (29.4%). Globally, positive cultures for
“typical” microorganisms (Online Refs. 11,12) were
obtained in about one-half of the patients with pre-
vious TVR (53.1% of TAVR patients and 47.1% of TPVR
patients). Less common causal agents included Gram-
negative bacilli in 3 cases, Corynebacterium (2 cases),
fungal infections (Candida albicans and Aspergillus
fumigatus), Histoplasma capsulatum, Bartonella hen-
selae, and Granulicatella adjacens (1 case each). In 2
patients, all cultures including those performed after
valve explantation, remained negative, but previous
antibiotic therapy had been administered in both
cases before blood samples were obtained.
MANAGEMENT AND OUTCOMES OF TVR-RELATED PVE.
All patients received antibiotic therapy according
to the etiology of PVE. Cardiac surgery and valve
explantation were performed in 13 patients (41%)
in the TAVR group and in 21 patients (75%) in the
TPVR group. In the TAVR group, the rate of PVE-related surgery was twice as high in patients
who had received a balloon-expandable valve (57%)
compared with those who had a self-expandable
valve (23%), despite a similar baseline risk proﬁle in
both groups as evaluated by the logistic EuroSCORE
(30.5  15.6% vs. 27.8  13.5% in balloon- and self-
expandable groups, respectively).
The most important surgical ﬁndings included
incomplete valve endothelialization several months
after TAVR in 1 case and sinotubular junction
penetration by the struts in another case (Online
Refs. 14,34).
The in-hospital mortality rate was 34.4% in the
TAVR group, 30.8% in those patients who had surgery
and valve explantation and 36.8% in those managed
medically. In the TPVR group, the in-hospital mor-
tality rate associated with the episode of PVE was
7.1%, 9.5% in patients who required surgery and none
in those managed medically. Follow-up data were
TABLE 1 Baseline Data of Patients With Previous Transcatheter Aortic Valve With Infective Endocarditis
Patient #
(Reference No.)
Age,
yrs Sex
Logistic
EuroSCORE Valve-in-Valve
Antibiotic Prophylaxis
Regimen Approach Valve
Valve Size,
mm Post-TAVR AR
1 (1) 85 M 25 No — TF Edwards SAPIEN XT* 26 —
2 (2) 83 F — No — TA Edwards SAPIEN 23 —
3 (3) 76 M 61.1 Yes — TA Edwards SAPIEN 23 —
4 (4) 80 F 14.2 No Cefazolin TA Edwards SAPIEN XT 23 —
5 (5) 80 M 30 No Nasal mupirocin TF CoreValve† 29 Mild
6 (5) 81 F 48 No — TA Edwards SAPIEN 23 Moderate
7 (5) 80 F 41 No — TA Edwards SAPIEN 23 Mild
8 (5) 85 M 23 No — TF Edwards SAPIEN 23 Moderate
9 (5) 91 F 25 No — TA Edwards SAPIEN 23 Trace
10 (6) 73 M 6.6 No — TF Edwards SAPIEN 26 Mild
11 (7) 64 F — No — TF CoreValve — —
12 (7) 81 M 40 No — TF CoreValve 29 Mild
13 (7) 83 F — No — TA Edwards SAPIEN 23 Trace
14 (7) 78 M — No — TF Edwards SAPIEN — —
15 (7) 66 M — No — TF CoreValve 29 Mild
16 (7) 88 M 35 No — TF Edwards SAPIEN 26 Trace
17 (7) 91 M — No — TA Edwards SAPIEN 23 Mild
18 (7) 84 M 24 No — TF CoreValve 29 Mild
19 (7) 85 M — No — TF CoreValve 29 —
20 (7) 80 M — No — TF CoreValve — —
21 (8) 84 M 23.5 No Vancomycin þ
ciproﬂoxacin
TF CoreValve 29 Mild
22 (9) 86 M — No — — — — —
23 (10) 81 M 29 No Ampicillin TF CoreValve 29 Moderate
24 (11) 72 F 39.7 Yes — TF Edwards SAPIEN 23 None
25 (12) 71 M 24.3 No — — Edwards SAPIEN 23 Moderate
26 (13) 75 F — No — — Edwards SAPIEN XT 26
27 (14) 84 M — No — TA Edwards SAPIEN XT
28 (15) 70 M 33.1 No — TF CoreValve Mild
29 (16) 72 M 28.1 No Cefazolin þ gentamicin TA Edwards SAPIEN 23 Mild
30 (16) 91 F 15.2 No Teicoplanin TF CoreValve 29 Trivial
31 (16) 88 F 55.3 No Cefazolin þ gentamicin TF CoreValve 29 Mild
32 (16) 90 M 26.5 Yes Cefazolin þ gentamicin TF CoreValve 29 Moderate
*Manufacturer: Edwards Lifesciences, Irvine, California. †Manufacturer: Medtronic, Minneapolis, Minnesota.
AR ¼ aortic regurgitation; TA ¼ transapical; TF ¼ transfemoral.
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338available in 15 patients in the TAVR group (47% of
study population, 71% of the patients alive at hospital
discharge), with a mean length of follow-up of 11 
9 months. Two additional cases of PVE-related death
were reported in this period, at 1 and 3 months after
hospital discharge. No follow-up information was
available for patients treated with TPVR, which pre-
cludes long-term prognostic conclusions.
The rates of surgical management and mortality in
TAVR and TPVR groups are summarized in Table 5.
DISCUSSION
PVE POST-TVR: INCIDENCE AND PREDISPOSING
FACTORS. Although the incidence of early PVE
post-TVR has been more than 2% in some small
series, larger studies have usually reported anincidence #1%, similar to that of surgical valve series
(Online Refs. 21–25). In the PARTNER trial, the inci-
dence of early PVE was 0.72%, which was comparable
to the 1% rate observed in the surgical cohort (Online
Ref. 6). However, one may wonder whether a lower
rate of early PVE should be expected among TAVR
patients, considering the less invasive nature of the
procedure.
Some concerns have been raised about the ade-
quacy of the sterile conditions in which the trans-
catheter valves are prepared and ﬁnally implanted.
Although no details were provided about the location
of TVR procedures in the reported cases of PVE, it is
well known that most procedures are performed in
the catheterization laboratory (Online Ref. 34), usu-
ally not achieving the same level of sterile conditions
as an operating or hybrid room. Although the rate of
TABLE 2 Baseline Data of Patients With Previous Transcatheter Pulmonary Valve With Infective Endocarditis
Patient #
(Reference No.)
Age,
yrs Sex Underlying Cardiopathy
Type of Surgical
Valve/Conduit
Time From
Surgery
to TPVR, yrs
Antibiotic
Prophylaxis
Regimen
Type of
Malfunction
Type of
Valve
1 (17) 15 M Truncus arteriosus Homograft 10 — Regurgitation Melody*
2 (18) 19 F Truncus arteriosus Homograft þ LV patch 15 — Stenosis/regurgitation Melody
3 (19) 4 M Tetralogy of Fallot with
pulmonic atresia
— — Cefazolin Stenosis Melody
4 (19) 25 M Double outlet right ventricle — — Cefazolin Stenosis Melody
5 (19) 21 M Tetralogy of Fallot — — Cefazolin Stenosis Melody
6 (19) 18 M Tetralogy of Fallot with
pulmonic atresia
— — Cefazolin Stenosis Melody
7 (20) — — — Homograft 2 (1–5)‡ — — Melody
8 (20) — — — Homograft 2 (1–5)‡ — — Melody
9† (21) — — Tetralogy of Fallot Homograft — — — Melody
10 (22) 24 M Congenital aortic stenosis
with Ross procedure
Homograft 8 — Stenosis Melody
11 (23) 14 M Congenital aortic stenosis
with Ross procedure
Homograft — — Stenosis/regurgitation Melody
12 (23) 18 F Tetralogy of Fallot Carpentier-Edwards
conduit
— — Stenosis Melody
13 (23) 26 M Tetralogy of Fallot Hancock conduit — — Stenosis/regurgitation Melody
14 (23) 11 M Tetralogy of Fallot Hancock conduit — — Stenosis Melody
15 (24) — M — Ven Pro conduit — — Stenosis Melody
16 (24) — M — — — — Stenosis Melody
17 (24) — M — — — — Stenosis Melody
18 (25) 16 M Congenital aortic stenosis
with Ross procedure
Homograft 11 — Stenosis Melody
19 (26) — — Truncus arteriosus Homograft — — — Melody
20 (26) — — Congenital aortic stenosis
with Ross procedure
Homograft — — — Melody
21 (26) — — — — — — — Melody
22 (26) — — — — — — — Melody
23 (26) — — — — — — — Melody
24 (27) 8 M Tetralogy of Fallot Stentless porcine valve — — Stenosis/regurgitation Melody
25 (27) 14 M Tetralogy of Fallot Stented porcine valve — — Stenosis Melody
26 (27) 20 M Tetralogy of Fallot Bovine valve conduit — — Stenosis/regurgitation Melody
27 (27) 11 M Tetralogy of Fallot Stented porcine valve — — Stenosis/regurgitation Melody
28 (28) 14 M Tetralogy of Fallot Carpentier-Edwards
conduit
6 — Stenosis/regurgitation Melody
*Manufacturer: Medtronic (Minneapolis, Minnesota). †Median age for the series: 21.5 years (16.2 to 30.1 years). ‡Median (interquartile range).
LV ¼ left ventricular; TPVR ¼ transcatheter pulmonary valve implantation; other abbreviations as in Table 1.
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339bacterial infection in coronary cases is low (0.64%),
positive blood cultures were obtained in 18% of
the patients after the procedure (Online Ref. 35).
Also, infective complications in the postoperative
period affect as many as 15% of the patients (Online
Ref. 36) and are a potential source of infection
for PVE. Finally, the compression of the leaﬂets dur-
ing transcatheter valve preparation and loading
can be associated with some leaﬂet damage
(Online Ref. 37), which indeed can favor the occur-
rence of PVE.
The present study showed that the vast majority of
patients with PVE post-TVR were men, with as many
as 66% and 90% of the patients in the TAVR and TPVRgroups, respectively. This is in accordance with pre-
vious PVE studies (Online Ref. 5), in which about two-
thirds of the patients with endocarditis were men.
The protective asset of the female sex could be
partially explained by the hypothetical endothelial
protection by estrogen (Online Ref. 38).
The present study suggests that patients with
endocarditis after TAVR are among those with the
highest risk proﬁle, with a mean logistic EuroSCORE
close to 30% and frequent comorbidities such as
diabetes, immunosuppression (i.e., steroids, myelo-
dysplastic syndromes), and renal failure that have
been recognized as predisposing factors for PVE
(Online Ref. 5).
FIGURE 3 Clinical Characteristics of TAVR Infective
Endocarditis Patients Compared With Previous
Transcatheter and Surgical Aortic Valve Series
Age* (A), sex* (B), and logistic EuroSCORE* (C) of TAVR infective
endocarditis patients (n ¼ 32) compared with patients included in
TAVR registries, the PARTNER trial, and surgical series of aortic
valve replacement with bioprosthesis. *From cases reporting
data (Online References). Abbreviations as in Figure 1.
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340Finally, the presence of residual AR is well recog-
nized as one of the most important limitations of
TAVR. In the present study, most patients (75%) with
echocardiographic data available had mild or greater
residual AR, a much higher rate compared with pre-
vious TAVR series (Online Refs. 6–9,19–22). The
presence of residual AR as a source of endothelial
damage that may act as anchoring for the germs
during episodes of transient bacteremia and its role as
a predisposing factor for PVE needs to be further
evaluated.
In TPVR patients, underlying congenital heart
disease or the type of conduit used to repair the right-
side anomalies were not related to a higher rate of
PVE, albeit the presence of homografts in patients
with PVE was w20% less frequent than in previous
TPVR studies (Figure 2). On the other hand, stenotic
malfunction of the percutaneous pulmonary valves
(isolated or combined with regurgitation) seemed to
be associated with a higher risk of PVE. Stenotic
conduits may be more deteriorated and calciﬁed and
with higher shear stress forces that may predispose to
PVE. However, previous studies have not clearly
demonstrated a higher incidence of PVE in stenotic
or regurgitant prosthetic or native valves (Online
Refs. 26–30).
Antibiotic prophylaxis before TVR and before
dental and other invasive procedures after TVR is
currently decided on a case-by-case basis or accord-
ing to institutional protocols, with the inherent limi-
tations and variability of such an individualized
strategy. This may also play a role in the occurrence
of early PVE post-TVR. Of note, gastrointestinal pro-
cedures such as colonoscopies no longer require
antibiotic prophylaxis as of 2009 European Society of
Cardiology guidelines (Online Ref. 11). Even if publi-
cation bias may overestimate this problem, several
patients included in this review presented with PVE
after such procedures; it is therefore necessary to
determine whether a step back in the recommenda-
tions may be necessary in TVR patients.
PVE POST-TVR: ETIOLOGY AND DIAGNOSTIC
FEATURES. Staphylococci, fungi, and gram-negative
bacilli have been found to be the main causes of
early prosthetic valve endocarditis (Online Ref. 11).
These “contaminant” germs were also a frequent
etiology of early PVE after TAVR (36.7%), with
enterococci as the predominant causative agents of
early PVE in this group (Table 5). Previous studies
predicted the increasing role of this pathogen as life
expectancy increases and more aggressive therapies
are administered to aged patients (Online Refs. 5,35).
Enterococci are highly tolerant to antibiotic-induced
FIGURE 4 Clinical Characteristics of TPVR Infective Endocarditis Patients Compared With Previous TPVR Series
Age (A), sex (B), underlying disease (C), type of conduit (D), and main reasons (stenosis vs. regurgitation) for TPVR (E) in TPVR infective endocarditis patients compared
with the largest series of TPVR. *See the Online References. Abbreviations as in Figures 1 and 2.
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341killing, and eradication requires prolonged adminis-
tration (as long as 6 weeks) of synergistic bactericidal
combinations. Moreover, these microorganisms can
be resistant to multiple drugs, including amino-
glycosides, beta-lactams, and vancomycin (Online
Ref. 35). This high rate of failure of antibiotics has
major implications, as isolated medical management
remains the most frequent strategy for the treatment
of PVE after TAVR.
With regard to echocardiographic ﬁndings, valve
prosthesis vegetation was present in about one-half
of the patients diagnosed with PVE post-TVR. In
TAVR patients, complications such as abscesses
(47%), ﬁstulae (9%), or the involvement of other
valves (22%) were relatively common and much more
frequent than that observed in previous series
including native and surgical prosthetic valves
(Online Refs. 21–25). On the other hand, in TPVR pa-
tients, the infection was limited to the valve pros-
thesis (either the leaﬂets, stent frame, or both) in all
cases.
The microbiological, structural, and clinical par-
ticularities of patients treated with TVR may reducethe sensitivity of the Duke criteria (Online Refs. 11,12).
Hence, some speciﬁc recommendations in this ﬁeld
may improve accuracy in the diagnosis of PVE (Online
Ref. 39).
PVE POST-TVR: MANAGEMENT AND OUTCOMES.
The rate of valve explantation in endocarditis studies
has been as high as 75% for native valves and 50% for
surgical bioprostheses (Online Ref. 40). In contrast,
the rate of valve explantation in cases of PVE post-
TAVR was 41%. Interestingly, this rate was much
higher in balloon-expandable cases (57%) than in self-
expandable ones (23%). Although many factors may
have played a role in the differences between valve
types, the much longer stent frame extending toward
the ascending aorta of the CoreValve (Medtronic)
system may increase technical difﬁculties during
surgical valve explantation and may have been
responsible for a lower rate of valve explantation in
these cases. The high-risk proﬁle of the patients un-
dergoing TAVR may explain patients’ refusal of valve
explantation in some of these cases even if more than
one-third of them had a local extension of the
TABLE 3 Main Symptoms, Imaging/Pathological and Microbiological Findings, and Outcomes of TAVR Patients With Infective Endocarditis
Patient #
(Reference No.)
Source of
infection Microorganism
Time from
TAVR, months Symptoms
Surgical
Management
Location (Echocardiographic
and Surgical Findings)
IE-Related
Death
1 (1) — Streptococcus angiosus — Stroke, fever Yes Leaﬂets vegetation,
incomplete
endothelialization
No
2 (2) — Enterococcus faecalis 6 Fever Yes Subvalvular abscess No
3 (3) — Unknown 48 Fever/negative cultures Yes Aortic root and tricuspid
abscess þ
tricuspid vegetation
Yes
4 (4) — Enterococcus faecalis 1 Hemiparesis, fever Yes Posterior mitral leaﬂet Yes
5 (5) — Staphylococcus aureus 7 CHF þ fever Yes Aortic root abscess with
pseudoaneurysm
Yes
6 (5) — Enterococcus faecalis 2 Fever No Valve stent No
7 (5) — Enterococcus faecalis 10 Local chills, minor stroke No Valve vegetation No
8 (5) Urologic Escherichia coli þ Proteus
mirabilis
5 Fever, Osler’s nodes No Only progression of AR Yes
9 (5) — Streptococcus gordonii 23 Fever No None No
10 (6) Dental Unknown 6 Asymptomatic/ negative
cultures
Yes Periaortic abscess, new
aortic regurgitation
No
11 (7) Respiratory tract
infection
Moraxella nonliquefaciens 2 Fever No Aorta pseudoaneurysm No
12 (7) PCI Staphylococcus
lugdunensis
19 Fever, CHF No PVL, LA ﬁstula, valve
vegetation
Yes
13 (7) Urological Enterococcus faecalis 3 Fever, CHF No Valve vegetation Yes
14 (7) — Histoplasma capsulatum 12 Fever Yes Valve vegetation No
15 (7) Pneumological Corynebacterium 3 Fever Yes Aortic pseudoaneurysm,
severe MR
due to leaﬂet
perforation
No
16 (7) Dental Streptococcus anginosus 11 Fever Yes Severe MR due to leaﬂet
perforation
No
17 (7) — Candida albicans — Fever No Increase of transaortic
gradient
Yes
18 (7) Valve reloaded Staphylococcus
epidermidis
2.5 Sepsis No None No
19 (7) — Enterococcus faecium 9 Loss of appetite No Suspected vegetation No
20 (7) Pneumological Staphylococcus
lugdunensis
0.5 Fever, dyspnea No Mitroaortic abscess, LA
ﬁstula
Yes
21 (8) — Staphylococcus
epidermidis
2.5 Sepsis No None No
22 (9) Dental Granulicatella adiacens 3 Purpura, interscapular
pain
No Valve vegetation Yes
23 (10) Colonoscopy Staphylococcus aureus 6 Fever, confusion, CHF No Valve stent vegetation No
24 (11) — Staphylococcus
epidermidis
5 Fever No Paravalvular abscess Yes
25 (12) Foot gangrene Pseudomonas aeruginosa 7 Fever, shivering, CHF Yes Valve vegetation No
26 (13) — Enterococcus faecium 8 Fever, CHF, palpitations Yes Valve vegetation Yes
27 (14) — Enterococcus durans 1 Not described Yes TAVR leaﬂets and annulus
abscess
No
28 (15) Spondylodiscitis Staphylococcus
epidermidis
12 Limb ischemia Yes Leaﬂets and stent
vegetation
(penetrating
sinotubular junction)
No
29 (16) — Enterococcus faecalis 3.5 Fever, chills, rigors No Aortic pseudoaneurysm
and mitral valve
vegetation
No
30 (16) PPMI Streptococcus mitis 0.5 Fever No Mitral valve No
31 (16) Pneumological Enterococcus faecium 1 Fever, chills No Aortic pseudoaneurysm No
32 (16) Cellulites Enterococcus faecalis 4 Cellulites (recurrent), CHF No New aortic regurgitation No
AR ¼ aortic regurgitation; CHF ¼ congestive heart failure; IE ¼ infective endocarditis; LA ¼ left atrial; PCI ¼ percutaneous coronary intervention; PPMI ¼ permanent pacemaker implantation; PVL ¼
paravalvular leak; TAVR ¼ transcatheter aortic valve implantation.
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TABLE 4 Main Symptoms, Imaging/Pathological and Microbiological Findings, and Outcomes of TPVR Patients With IE
Patient #
(Reference No.)
Source of
infection Microorganism Symptoms Surgical Management
Location (Echocardiographic
and Surgical Findings) IE-Related Death
1 (17) — Bartonella henselae Fever Yes Vegetation at struts No
2 (18) — Staphylococcus aureus Fever Yes Vegetation at cusps No
3 (19) Dental Streptococcus viridans Fever No — No
4 (19) Pneumological — Pneumonia No — No
5 (19) — — Circadian febrile episodes,
malaise for 3–4 days
No — No
6 (19) Pneumological — Fever, cough, malaise Yes — No
7 (20) — Staphylococcus aureus Fever Yes None No
8 (20) — Staphylococcus aureus Fever Yes Vegetation at cusps No
9 (21) — Staphylococcus aureus — Yes Vegetation at struts No
10 (22) — Haemophilus
parainﬂuenzae
Fever, cough, vomiting No Vegetation at 2 of the 3
cusps
No
11 (23) — Streptococcus sanguinis Fever, CHF (right failure) Yes Vegetation at cusps No
12 (23) — Streptococcus sanguinis Fever, CHF (right failure),
shock liver
Yes Large obstructive
vegetation
Yes
13 (23) — Staphylococcus
epidermidis
Fever, CHF (right failure),
light headedness
Yes, urgent (<24 h) Vegetation at cusps Yes
14 (23) — Streptococcus mitis Fever, macrophage
activation syndrome
Yes Calciﬁcation and
inﬂammation of
leaﬂets with infective
thrombus
No
15 (24) — — Fever Yes Vegetation No
16 (24) — — Fever Yes Vegetation No
17 (24) — — Fever Yes None No
18 (25) — Aspergillus fumigatus CHF (no fever); cardiac
arrest that forced
emergent
cardiopulmonary
bypass and surgery
Yes, emergent Thrombus infected with
Aspergillus
No
19 (26) Dental Staphylococcus aureus Fever Yes — No
20 (26) Previous fungal
infection
Staphylococcus aureus,
Streptococcus
aurelius, Candida
albicans
Fever Yes — No
21 (26) Skin infection Staphylococcus aureus,
Streptococcus
aurelius, Candida
albicans
Fever Yes — No
22 (26) Previous IE Staphylococcus aureus,
Streptococcus
aurelius, Candida
albicans
Fever No — No
23 (26) Previous IE Staphylococcus aureus,
Streptococcus
aurelius, Candida
albicans
Fever No — No
24 (27) Skin infection Streptococcus viridans CHF No None No
25 (27) — Corynebacterium Fever Yes PS þ vegetation No
26 (27) — Streptococcus sanguinis Fever Yes PS þ vegetation No
27 (27) — Staphylococcus aureus CHF (requiring ECMO) Yes PS No
28 (28) — Corynebacterium
pseudodiphtheriticum
Low-grade fever,
lethargy, and anorexia
Yes Vegetation at cusps No
ECMO ¼ extracorporeal membrane oxygenation; PS ¼ pulmonary stenosis; other abbreviations as in Tables 2 and 3.
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343infection and a signiﬁcant number (30%) had com-
plications such as heart failure and embolism that are
frequent reasons to decide on surgery (Online
Refs. 11,12). Indeed, about two-thirds of the patients
with heart failure at admission were not operated ondespite the proven survival beneﬁts of surgery in that
scenario (Online Refs. 11,41).
The rate of valve explantation observed in PVE
post-TPVR was as high as 75%. Apart from the fact
that the TPVR population is much younger than the
FIGURE 5 Timing of Infective Endocarditis After Transcatheter Aortic Valve
Replacement and Transcatheter Pulmonary Valve Replacement
Time from transcatheter valve replacement to infective endocarditis onset of symptoms in
transcatheter aortic valve replacement and transcatheter pulmonary valve replacement
patients.
FIGURE 6 Location
Schematic location o
transcatheter aortic v
had vegetation in mu
for 19 of the 28 pati
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344usual IE patients, the right-side location (Online
Refs. 41,42) and etiology of the endocarditis in such
cases (S aureus as the most frequent agent) may
explain the high valve explantation rate (Online
Refs. 41,43).of Infective Endocarditis After Transcatheter Valve Replacement
f infective endocarditis according to echocardiographic and/or pathological ﬁn
alve replacement (information available in all 32 patients included in the revie
ltiple locations. (B) Location of infective endocarditis in patients with previo
ents included in the review).Interestingly, the surgical explantation of many of
these infected transcatheter valves and previous
autopsy series (Online Refs. 43–45) have contributed
to a better understanding of the predisposing
anatomic factors, including extensive inﬂammatory
reactions (Online Ref. 45), infection of the skirt and
leaﬂets with extension and perforation of adjacent
structures (Online Ref. 44), and (more controversial)
the lack of valve endothelialization or thrombotic
complications (Online Refs. 46–49). Also, Loeser
et al. (Online Ref. 43) reported that signs suggestive
of PVE after TAVR may be more frequent than
commonly thought.
PVE has been associated with a high mortality rate
(20% to 40%), with no major improvements in the
survival rate of this life-threatening disease in the
past 30 years (Online Ref. 11). The mortality rate
observed in TAVR patients who had PVE (34%) was in
accordance with such data, even though we cannot
exclude a potential underestimation of the real
mortality rate due to a publication bias (authors may
tend to publish the cases that end well). The 7%
mortality rate in TPVR patients that may seem low
appears to be too high if we take into consideration
the young population involved. Overall, this high-
lights the importance of maximizing the measures of
asepsis and appropriate antibiotic prophylaxis and
prompts us to think about the most appropriate
strategy for the treatment of PVE post-TVR. The
possibility of earlier and more frequent valvedings. (A) Location of infective endocarditis in patients with previous
w). Thirteen patients had vegetation in 1 location, whereas 3 patients
us transcatheter pulmonary valve replacement (information available
TABLE 5 Comparative Information of TAVR and TPVR
Patients With IE
Variable
TAVR
(n ¼ 32)
TPVR
(n ¼ 28)
Initial symptoms
Fever 25 (78.1) 24 (85.7)
Heart failure 8 (25) 6 (21.4)
Neurological 4 (12.5) 0 (0)
Early IE 24 (95.2) 18 (69.6)
Echocardiographic characteristics
Presence of vegetation 12 (37.5) 13 (46.4)
Located in the transcatheter valve 23 (71.9) 28 (100)
Microbiological characteristics
Typical microorganisms* 17 (53.1) 8 (47.1)
Contaminant agents in early IE† 11 (36.7) 9 (56.2)
Staphylococcus aureus 2 (6.2) 5 (29.4)
Staphylococcus epidermidis 4 (12.5) 1 (5.9)
Enterococci 11 (34.4) 0 (0)
Management and outcomes
Surgical treatment 13 (40.6) 21 (75.0)
IE-related death 11 (34.4) 2 (7.1)
Values are n (%). Percentage provided according to the total number of patients
who provided the issued information. *Typical microorganisms according to
modiﬁed Duke criteria (16): Streptococcus viridans, Streptococcus bovis, HACEK
group, Staphylococcus aureus, or enterococci. †Contaminant microorganisms
include those more frequently leading to early prosthetic valve endocarditis
(Staphylococcus epidermidis, Staphylococcus aureus, Gram-aerobic agents, and
fungi).
Abbreviations as in Tables 1 to 3.
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345explantation in such cases to improve prognosis
(Online Ref. 50) may be considered. Although major
differences in the clinical proﬁle between the TAVR
and TPVR groups probably explain the differences in
mortality rate, the higher rate of surgical treatment
among TPVR patients may have contributed to the
better outcomes compared with TAVR candidates.
Further studies are needed to evaluate whether sur-
gery improves outcomes despite the complex inter-
vention and the risk of recurrent infection estimated
at 15% after PVE (Online Refs. 40,51).
STUDY LIMITATIONS. The present study has the
limitations inherent to a systematic review that col-
lects only the information described in the publica-
tions. Therefore, there might be relevant information
omitted in the publications that could shed some light
on this limitation. This also includes incomplete
echocardiographic data, particularly regarding the
characteristics (size, mobility) of the vegetation. In
addition, all of the published papers found were
either case reports or very small series, precluding
comparison with the entire TVR population at risk.
Additionally, the patients reported might have ten-
ded to have a better outcome than those who were
not reported (selection bias).CONCLUSIONS
PVE is an uncommon but life-threatening complica-
tion after TVR. Although the conditions of asepsis
are frequently less strict than in surgical in-
terventions, the incidence of early PVE post-TVR re-
mains low (usually #1%) and similar to that of
surgical series. In the TAVR population, this compli-
cation seems to be more frequent in male patients
and in those with higher risk proﬁle. In TPVR pa-
tients, PVE seems to occur more frequently in male
patients with a stenotic (vs. regurgitation) conduit/
valve as the main underlying disease. Although early
PVE is considered to be acquired during the peri-
procedural time, the low rate of classic contaminant
agents in favor of others such as enterococci, espe-
cially among TAVR patients, may suggest alternative
source of infection. This is of major clinical impor-
tance because alternative antibiotic prophylaxis
protocols may reduce the incidence of the disease.
About two-thirds of the TAVR-PVE patients were
managed medically, despite the fact that more than
one-half of the patients had complications such as
local extension, embolism, and heart failure. The
mortality rate of PVE in these patients was high
(more than 30%) and similar to that described in
previous PVE studies. Most TPVR-PVE patients were
managed surgically and underwent surgical explan-
tation of the infected conduit valve. However, the
mortality rate remained at 7% despite the very young
age of this population.
The syndromic characteristics of PVE vary accord-
ing to the underlying disease and the microorganism
involved. PVE in transcatheter valve carriers repre-
sents a paradigm shift in PVE proﬁle, involving very
old (and high risk) or very young patients, both with a
high rate of health-care procedures. This systematic
review represents a ﬁrst step toward a better under-
standing of the proﬁle conditions and predisposing
factors, etiology, management, and prognosis of PVE
in patients with transcatheter valves. Future studies
will have to determine the potential usefulness
of improving asepsis/antibiotic prophylaxis in this
challenging group of patients and ﬁnding a better
strategy for an earlier diagnosis and better manage-
ment to decrease the incidence of PVE and increase
the survival associated with this life-threatening
complication.
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